No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer

doi:10.3748/wjg.v28.i38.5589

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4253)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

171

WORD

HTML

1671

Figures (1-4)

196

Tables (1-3)

184

Sum=2257

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

223

Download

507

Sum=730

Publishing Process of This Article

Item

Count

Browse

298

Download

968

Sum=1266

Oct 14, 2022 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589

Full Size Figure Download Figure

Figure 3 Survival Outcomes in gastric cancer patients. A: Overall survival analysis in all gastric cancer patients; B: Overall survival analysis in stage II gastric cancer patients; C: Overall survival analysis in stage III gastric cancer patients. NSR: Non-sustained-release.

Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589